Gata3/Long Noncoding Rna Mhc-R Regulates the Immune Activity of Dendritic Cells in Chronic Obstructive Pulmonary Disease Induced by Air Pollution Particulate Matter

He, Fang; Wang, Nian; Yu, Xiaoyuan; Zheng, Yufan; Chen, Qingzi; Li, Qun; Li, Naijian; Zou, Weifeng; Li, Bing; Ran, Pixin

doi:10.2139/ssrn.4064406

Cited by 1 publication

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[262][263][264][265][266][267] DCs, considered professional APCs, make up approximately 0.3% of the total cell population in the blood and can promote the proliferation and differentiation of CTLs. 268,269 Moreover, the quantity of DCs is strongly associated with the survival time of patients. 270,271 Therefore, DC-based vaccines are the most common vaccination approach for pediatric sarcomas, and patients who received a DC vaccine had a prolonged survival time compared with control patients.…”

Section: Conventional Immunotherapy For Osteosarcomamentioning

confidence: 99%

Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment

Tian

Cao

et al. 2023

Bone Res

View full text Add to dashboard Cite

Osteosarcoma, with poor survival after metastasis, is considered the most common primary bone cancer in adolescents. Notwithstanding the efforts of researchers, its five-year survival rate has only shown limited improvement, suggesting that existing therapeutic strategies are insufficient to meet clinical needs. Notably, immunotherapy has shown certain advantages over traditional tumor treatments in inhibiting metastasis. Therefore, managing the immune microenvironment in osteosarcoma can provide novel and valuable insight into the multifaceted mechanisms underlying the heterogeneity and progression of the disease. Additionally, given the advances in nanomedicine, there exist many advanced nanoplatforms for enhanced osteosarcoma immunotherapy with satisfactory physiochemical characteristics. Here, we review the classification, characteristics, and functions of the key components of the immune microenvironment in osteosarcoma. This review also emphasizes the application, progress, and prospects of osteosarcoma immunotherapy and discusses several nanomedicine-based options to enhance the efficiency of osteosarcoma treatment. Furthermore, we examine the disadvantages of standard treatments and present future perspectives for osteosarcoma immunotherapy.

show abstract